More on China Cord Blood earnings

|About: China Cord Blood Corporation (CO)|By:, SA News Editor

China Cord Blood (CO) posts a mixed FQ1, beating on its EPS but missing slightly on top line revenue.

Total sales increased by 11.6% Y/Y, driven by higher storage fees.

Accumulated subscriber base grew to 327,242, +27.7% year-over-year.

Gross margin increased to 81% from 78.9% in the prior year period.